

# Mark A Fiala Msw

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2494500/publications.pdf>

Version: 2024-02-01

129  
papers

2,090  
citations

279798

23  
h-index

265206

42  
g-index

130  
all docs

130  
docs citations

130  
times ranked

3316  
citing authors

#	ARTICLE	IF	CITATIONS
1	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.4	11
2	Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. <i>Scientific Reports</i> , 2022, 12, 30.	3.3	12
3	Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 573-585.	1.8	4
4	Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1213-1215.	2.4	1
5	Screening recommendation adherence among first-degree relatives of individuals with colorectal cancer. <i>Translational Behavioral Medicine</i> , 2022, 12, 853-859.	2.4	1
6	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	4.1	20
7	Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e152-e159.	0.4	14
8	Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". <i>Annals of Hematology</i> , 2021, 100, 1261-1266.	1.8	7
9	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018.	2.4	2
10	Co-evolution of tumor and immune cells during progression of multiple myeloma. <i>Nature Communications</i> , 2021, 12, 2559.	12.8	68
11	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704.	1.4	4
12	A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3043-3046.	1.3	1
13	Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1005-1009.	1.0	4
14	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 19343.	3.3	6
15	Utilization of radiation therapy in multiple myeloma: trends and changes in practice. <i>Annals of Hematology</i> , 2021, 100, 735-741.	1.8	4
16	VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. <i>Clinical Cancer Research</i> , 2021, 27, 1974-1986.	7.0	17
17	Disparities in health care affordability among childhood cancer survivors persist following the Affordable Care Act. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29370.	1.5	0
18	3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2690-2690.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Financial Toxicity Among Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 4027-4027.	1.4	2
20	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2021, 138, 2691-2691.	1.4	0
21	Cost differential associated with hospice use among older patients with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 88-92.	1.0	7
22	A comparison of three different approaches to defining frailty in older patients with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 311-315.	1.0	19
23	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1188-1190.	2.4	1
24	Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 98-104.e1.	0.4	16
25	Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER Medicare database. <i>Cancer</i> , 2020, 126, 808-813.	4.1	23
26	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	1.3	6
27	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e937-e943.	0.4	6
28	Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1279-1284.	1.0	10
29	Evolution and structure of clinically relevant gene fusions in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 2666.	12.8	31
30	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	2.9	8
31	Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 647-651.	0.4	15
32	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1274-1278.	1.0	12
33	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1041-1048.	1.8	12
34	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	5.2	16
35	Mobilization Strategies: HPC(A) Collections for Allogeneic Hematopoietic Cell Transplants. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2020, , 63-80.	0.0	0
36	Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data. <i>Blood</i> , 2020, 136, 4-5.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study. <i>Blood</i> , 2020, 136, 13-13.	1.4	1
38	D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 26-27.	1.4	2
39	A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
40	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	1.3	13
41	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	1.3	23
42	A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e521-e525.	0.4	4
43	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 744-750.	0.4	7
44	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 285-289.	0.4	17
45	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e588-e593.	0.4	6
46	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	7.2	385
47	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3776-3783.	7.0	14
48	African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. <i>Cancer</i> , 2019, 125, 2321-2322.	4.1	0
49	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	1.4	10
50	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. <i>Blood</i> , 2019, 134, 602-602.	1.4	10
51	Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma. <i>Blood</i> , 2019, 134, 5531-5531.	1.4	1
52	Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy. <i>Blood</i> , 2019, 134, 5886-5886.	1.4	1
53	Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. <i>Blood</i> , 2019, 134, 4774-4774.	1.4	1
54	Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. <i>Blood</i> , 2019, 134, 364-364.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. <i>Blood</i> , 2019, 134, 4379-4379.	1.4	0
56	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5701-5701.	1.4	0
57	The Ire of IRE1 $\pm$ : Overexpression of IRE1 $\pm$ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1 $\pm$ Expression Is Predictive of Therapy Resistance. <i>Blood</i> , 2019, 134, 4351-4351.	1.4	1
58	Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 219-224.	0.4	34
59	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. <i>Nature Communications</i> , 2018, 9, 455.	12.8	150
60	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41
61	Falls in older adults with multiple myeloma. <i>European Journal of Haematology</i> , 2018, 100, 273-278.	2.2	15
62	Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	2.1	27
63	The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1483-1486.	2.4	12
64	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e363-e364.	0.4	4
65	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. <i>Blood Cancer Journal</i> , 2018, 8, 35.	6.2	41
66	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. <i>Blood</i> , 2018, 132, 123-123.	1.4	6
67	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. <i>Blood</i> , 2018, 132, 3233-3233.	1.4	6
68	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. <i>Blood</i> , 2018, 132, 3303-3303.	1.4	1
69	Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?. <i>Blood</i> , 2018, 132, 614-614.	1.4	5
70	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	1.4	10
71	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. <i>Blood</i> , 2018, 132, 5666-5666.	1.4	1
72	D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 2021-2021.	1.4	1

#	ARTICLE	IF	CITATIONS
73	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4463-4463.	1.4	0
74	Disparities in Healthcare Resource Utilization for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4793-4793.	1.4	1
75	Characterization of Germline Variants in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4499-4499.	1.4	0
76	A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2146-2146.	1.4	0
77	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 5627-5627.	1.4	1
78	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3439-3439.	1.4	0
79	Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium. <i>Blood</i> , 2018, 132, 1931-1931.	1.4	0
80	Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort. <i>Blood</i> , 2018, 132, 1898-1898.	1.4	0
81	Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm. <i>Blood</i> , 2018, 132, 1893-1893.	1.4	0
82	The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 241-243.	1.3	0
83	Racial disparities in treatment use for multiple myeloma. <i>Cancer</i> , 2017, 123, 1590-1596.	4.1	77
84	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
85	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. <i>Blood</i> , 2017, 129, 2680-2692.	1.4	66
86	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1072-1077.	2.0	39
87	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	1.8	7
88	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2065-2069.	2.0	19
89	Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.4	3
90	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-8.	2.1	12

#	ARTICLE	IF	CITATIONS
91	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. <i>Blood</i> , 2017, 130, 862-862.	1.4	0
92	Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities. <i>Blood</i> , 2017, 130, 860-860.	1.4	0
93	Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. <i>Transfusion</i> , 2016, 56, 2331-2335.	1.6	7
94	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	4.1	83
95	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.8	31
96	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 728-730.	1.3	14
97	A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 453-455.	1.3	0
98	The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. <i>Blood</i> , 2016, 128, 3563-3563.	1.4	2
99	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	1.4	0
100	Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2349-2349.	1.4	0
101	Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data. <i>Blood</i> , 2016, 128, 2084-2084.	1.4	0
102	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 1106-1110.	4.1	19
103	Personalization of cancer treatment using predictive simulation. <i>Journal of Translational Medicine</i> , 2015, 13, 43.	4.4	23
104	Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2643-2649.	1.3	47
105	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. <i>Diabetes</i> , 2015, 64, 2969-2977.	0.6	50
106	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769.	2.0	143
107	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1153-1154.	2.0	14
108	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3098-3098.	1.4	1

#	ARTICLE	IF	CITATIONS
109	A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 516-516.	1.4	3
110	A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants. <i>Blood</i> , 2015, 126, 4207-4207.	1.4	0
111	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 1366-1370.	2.4	6
112	Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. <i>International Journal of Hematology</i> , 2014, 99, 272-278.	1.6	32
113	PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. <i>British Journal of Haematology</i> , 2014, 165, 89-101.	2.5	34
114	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 337-341.	1.3	12
115	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 131-139.e1.	0.4	54
116	Therapy Personalization Using Predictive Simulation Approach with Ex-Vivo Clinical Validations. <i>Blood</i> , 2014, 124, 2232-2232.	1.4	1
117	Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. <i>Blood</i> , 2014, 124, 555-555.	1.4	24
118	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. <i>Blood</i> , 2014, 124, 1931-1931.	1.4	4
119	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 2456-2456.	1.4	1
120	Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 5696-5696.	1.4	0
121	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5292-5292.	1.4	0
122	A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4731-4731.	1.4	0
123	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 850-850.	1.4	0
124	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 5492-5492.	1.4	3
125	Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. <i>Blood</i> , 2011, 118, 809-809.	1.4	0
126	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. <i>Blood</i> , 2011, 118, 1024-1024.	1.4	0

#	ARTICLE	IF	CITATIONS
127	High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. Blood, 2011, 118, 1830-1830.	1.4	0
128	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. Blood, 2010, 116, 3803-3803.	1.4	2
129	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) $\geq$ 10,000 Copies/ML or $\geq$ 5,000 Copies/ML X 2. Blood, 2008, 112, 4340-4340.	1.4	0